The phase 3 trial by Bachert et al. (mentioned earlier under Tissue IgE) also found that in CRSwNP patients, treatment with dupilumab reduced levels of plasma eotaxin-3 [39]. Here, CCL26 is linked to chronic rhinosinusitis with nasal polyps.